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Abstract
Macular oedema is a known side effect to fingolimod, but changes in specific areas of the retina and the retinal nerve 
fiber layer are only sparsely described. Our aim was to investigate the prevalence of macular oedema and characterize 
macular changes after initiation of fingolimod based on routine ophthalmological examinations in all consecutive 
patients treated at our hospital. We evaluated macular thickness change from baseline to 3-4 months after initiation of 
treatment. Central retinal thickness, total macular volume, total macular thickness, average thickness and inner-/outer 
macular thickness was automatically measured using optical coherence tomography (OCT). A total of 190 eyes 
completed the study and none of those developed visible macular oedema. All macular areas showed a small, but 
statistically significant increase in thickness. Total macular volume increased by a mean of 0.05 mm3 (p = < 0.001). 
Mean best-corrected visual acuity only changed by 0.03 (p = 0.074). We observed a minimal change in macular 
thickness and no clinically relevant affection on visual acuity after 3-4 months of fingolimod treatment. Thus, our 
results do not underpin the need for routine screening for macular oedema in asymptomatic MS patients without 
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Fingolimod (Gilenya) is a spingosine-1-phosphate (S1P1) receptor modulator acting on G-protein-coupled S1P1-
receptors on peripheral lymphocytes by retaining both naive- and central memory T-cells [1]. Fingolimod was 
registered in 2011 for use in relapsing remitting multiple sclerosis (RRMS), primarily as second-line therapy or in 
patients with rapidly evolving severe disease [2]. The recommended dose in adults is 0.5 mg once daily [2].  
Two cases of macular oedema occurring in early studies of fingolimod with daily doses of 2.5 and 5 mg for 
renal transplant recipients [3] triggered the awareness of this complication, and led to the introduction of ophthalmic 
examinations of study patients [4]. Thus, macular oedema was found in up to 3.4% of patients treated with 5 mg with 
a trend towards a dose-related frequency [3, 5]. Later, 19 cases of macular oedema were identified amongst 2615 
patients in the clinical trials FREEDOMS [6] and TRANSFORMS [7] and their extensions evaluating fingolimod in 
lower doses for RRMS [4]. Again, the occurrence was dose-related with a prevalence of 1.2 % and 0.3% in patients 
receiving 1.25 mg and 0.5 mg daily, respectively. 
The manufacturer of Gilenya recommends ophthalmic examinations after 3-4 months’ treatment in all 
patients as well as before initiation in patients with a prior history of uveitis or diabetes [2]. However, a baseline and 
3-4-month follow-up ophthalmological examination including optical coherence tomography (OCT) has routinely 
been performed in all patients treated with fingolimod at Aalborg University Hospital since 2011. The aim of the 
present study was to investigate the outcome of these ophthalmic examinations in order to evaluate the prevalence of 
macular oedema and to investigate changes in the macula and optic disc nerve fibre layer.
Methods
Patients
We identified all patients treated with fingolimod at the department of Neurology, Aalborg University Hospital, 
between 1 January 2011 and 1 May 2018. All participants met the revisited 2005 International Panel MS diagnostic 
criteria [8]. In accordance with the screening program, the patients had a macular OCT and when possible an optic 
disc OCT performed right before and 3-4 months after initiation of treatment with fingolimod. We included those with 
a valid OCT at both visits. Eyes with a known retinal or macular disease expected to affect macular thickness per se or 
eyes that had undergone surgery less than 6 months prior to treatment with fingolimod or during the observation 
period were excluded from the study.
Collected data
Central retinal thickness (CRT), total macular volume (TMV), total macular thickness (TMT), average thickness as 
well as inner and outer macular thickness were automatically calculated by the TOPCON ImageNet 6 software. Scans 
were obtained by trained personnel using TOPCON Triton Swept source OCT, and data from both eyes, if possible, 
were analysed. The average of the four inner macular sectors and the four outer macular sectors were calculated and 
defined as inner and outer ring thickness. There is no defined cut-off value to signify minimally, clinically relevant 
change in macular thickness. Visual acuity served as an indicator of clinical significance of possible changes in 
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retinopathy or other retinal disease), refraction and medication apart from fingolimod were also obtained from the 
patient journal. Macular oedema was defined as visible intraretinal cysts or subretinal fluid on OCT.
In accordance with Danish legislation (Act on Research Ethics Review of Health Research Projects § 14 
subsection 2, dated 15 September 2017 and the Danish Health Act § 46 subsection 2, dated 2 November 2018), the 
Danish Patient Safety Authority approved the project including transmission of data from the patient records. The 
study was registered at the Danish Data Protection Agency and data were handled in accordance with the general data 
protection regulation. The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology 
policy for experimental and clinical studies [9].
Statistics
Data were entered in REDCapTM(Vanderbilt, USA) electronic data capture tools hosted at Aalborg University and 
statistical analysis was performed using STATA version 15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. 
College Station, TX, USA: StataCorp LLC). Distribution of data was evaluated using histograms and q-norm plots. 
Parametric data are presented as means with 95% confidence intervals (95% CI) or means ± standard deviations (SD) 
and non-parametric data as medians with interquartile ranges. To evaluate mean difference in OCT measurements 
before and 3-4 months after initiation of fingolimod treatment, we used a paired t-test in data following a normal 
distribution. Non-parametric data were analysed using Wilcoxon signed rank test. To evaluate whether patients with 
other eye disease were more prone to develop changes in OCT measurements, we compared the mean change in each 
parameter between eyes with a known diagnosis of the relevant disease to eyes without the diagnosis, using Student’s 
t-test.
Results
We identified a total of 138 patients or 276 study eyes treated with a standard dose of 0.5 mg fingolimod daily. 
Demographics and clinical features of the population are shown in Table 1. Nineteen patients had only one of the two 
examinations performed, and twenty-three patients did not show up at any of the planned examinations because they 
either changed department during the period, missed their appointments or were never referred to the department of 
ophthalmology. Two eyes were excluded as a result of concomitant retinal/macular disease and poor OCT quality 
(Figure 1). In twelve eyes, the software was unable to calculate average macular thickness and TMV, mainly because 
of reduced scan quality due to opacities in the anterior part of the eye.
None of the eyes showed visible macular oedema at baseline or follow-up. When considering all eyes, both 
average thickness, CRT, TMV, TMT and inner-/outer macula changed significantly (Table 2). The inner macula 
seemed slightly more prone to increase in thickness compared to the outer part. TMV increased by a mean of 0.05 
(0.03, 0.07) mm3 (p = < 0.001). In percentages TMV, average thickness and CRT increased by 0.68%, 0.69% and 
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Mean best-corrected visual acuity (BCVA) at baseline was 1.04 Snellen and 1.01 at 3 months yielding a non-
significant mean change of 0.03 (p = 0.074).
Eleven eyes (5.8%) were reported having visual disturbances during the observation period. In spite of the 
symptoms, only one eye experienced a decrease in BCVA > 1 line (from 1.4 to 0.4). Seven of the eyes with visual 
disturbances had a prior history of optic neuritis and a small increase in either TMV or average thickness occurred in 
four of those.
Eight eyes (four patients) in total had either a previous history of uveitis, a diagnosis of diabetes or cataract 
surgery done prior to fingolimod treatment and none of them showed any sign of macular oedema or significant 
macular thickness difference after 3-4 months compared to baseline. Eleven patients were registered using medication 
other than fingolimod at the time of fingolimod initiation. Forty-two patients had a history of previous optic neuritis. 
Comparing the macular changes in the optic neuritis group to the non-optic neuritis group demonstrated no significant 
difference in any of the given parameters. 
Discussion
To our knowledge, this is the largest study of macular findings in real-world consecutive fingolimod-treated patients 
so far. The main findings are that no patients developed visible macular oedema and that both thickness and volume of 
the macular area increased during 3-4 month follow-up after initiation of treatment. Although statistically significant, 
the little change in macular thickness we found is less than the normal inter-individual variance, [10] and we do not 
consider it clinically relevant. In fact, we found no relation between change in thickness and reported visual 
disturbance or change in BVCA, and the mean BCVA for the whole group was normal for this age group at both 
baseline and 3-4 month follow-up. Only a few patients reported visual disturbances and the majority of those had a 
history of optic neuritis prior to fingolimod treatment.
The findings that none of our patients developed macular oedema is in agreement with other studies showing 
a frequency of macular oedema of 0.3% in patients treated with the 0.5 mg dose used in RRMS [4]. The rare 
occurrence is supported by several post marketing studies emerging in recent years mentioning a total of eight cases of 
macular oedema amongst almost 2000 patients [11-20]. The finding of small increases in macular thickness and 
volume is also in line with a previous study of Nolan et al. that showed a small but significant difference in macular 
volume between MS patients treated with fingolimod and patients never treated with fingolimod [21]. The study 
included 30 patients in each group and not unlike our results, the TMV increased by 0.03 μm in the fingolimod group 
compared with no change in the control group. Another recent study, published in 2018 by Fruschelli et al [22]. with a 
population comparable to ours, found no statistically significant change in TMV at three, six or twelve months after 
initiation of fingolimod. Importantly, there was no significant change in visual acuity during the observation period in 
any of the two studies and in general the changes in macular thickness seemed to be small.
It is known that S1P1 receptors are important in promoting endothelial barrier integrity. The opposite is true 
with fingolimod, which is acting as an S1P1 antagonist leading to cell cytoskeleton rearrangement, increased vascular 
permeability and interrupted intercellular adhesion [23,24]. This may suggest that fingolimod is a main contributor to 
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with placebo in the FREEDOMS trial as compared to 0.8% in the actively treated group [4], suggesting that macular 
oedema is not exclusively a problem in fingolimod-treated patients. In continuation hereof, it has been discussed 
whether increase in retinal thickness and macular oedema is a side effect of fingolimod or simply a consequence of 
MS activity itself. In fact, up to 5% of MS patients in general show micro cystic macular oedema and the severity of 
the oedema corresponds to the severity of MS [25]. After all, the change in therapy to fingolimod comes as a 
consequence of disease activity and is therefore a possible confounder. An RCT from 2014 by Ocwieja et al. looked at 
healthy persons treated with either fingolimod 0.5 mg, 1.25 mg or placebo and found no change in macular thickness 
in either of the groups [26]. However, their observation period was only 4 weeks, but to some extent, it is clearly 
questioning the role of fingolimod in retinal thickness changes. Furthermore, it has been suggested that the increase in 
retinal thickness is not necessarily a negative side effect but rather a neuroprotective effect of S1P-receptor-
modulators in CNS [27-29]. Altogether, it is difficult to determine the isolated role of fingolimod in the pathogenesis 
of the small retinal changes we observed. As mentioned, altered disease severity may also play a role, and the lack of 
a control group in order to address this is a limitation of our study. 
In order to evaluate the value of the ophthalmological examinations at 3-4 months after fingolimod initiation, 
it is important to know whether retinal changes and macular oedema might appear later on, beyond the 4 months of 
our study. The findings by Zarbin et al. showed that most cases of macular oedema in their study presented themselves 
with symptoms within 3-4 month of treatment [4]. Furthermore, the extension studies in both FREEDOMS and 
TRANSFORMS observed fingolimod-treated patients for 24 and 48 months, respectively, and found no increase in 
cases of macular oedema during this period [30, 31]. This gives us reason to believe that most of the presumed 
fingolimod-induced retinal changes is happening during the first few months. Hence, it seems safe to perform the 
ophthalmologic screening at this time. However, the examinations are also time-consuming, and it can be speculated 
how much safety these visits add to the treatment of the RRMS patients, and if they are worth the costs. The low 
prevalence implies that 300 examinations can be expected in order to identify one case of macular oedema. 
Furthermore, in the study by Zarbin et al., the majority of patients with macular oedema presented with symptoms [4], 
and the condition was reversible upon withdrawal of fingolimod in more than 80% of cases. Diabetes, a history of 
uveitis and age above 41 years have been identified as risk factors. That taken into account, it may be considered to 
restrict the ophthalmic examinations to those with symptoms or with risk factors in order to allocate resources more 
appropriately. 
There are a number of limitations to our study. For one thing, we could not compare the observed small 
changes in macular thickness observed after 3-4 months of fingolimod treatment with an age-matched control group, 
because we do not routinely perform OCT scans repeatedly with 3-4 month intervals in MS patients not treated with 
fingolimod  Also, it is an important limitation of this study that it is not possible to objectively determine whether 
changes in OCT are entirely due to the effect of fingolimod. An influence of e.g. disease activity and concomitant 
symptomatic treatment with other medications cannot be excluded. Concomitant medication was only noted in the 
patient records of eleven patients, but we cannot be ascertained that all medications prescribed by e.g. general 
practitioners were listed here. Furthermore, one third of all treated patients were lost to follow-up and we do not know 
the ophthalmological outcome in these cases. Finally, the population is rather small to conclude on the prevalence of 
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fingolimod on macular thickness in patients with these risk factors cannot be appreciated from our results. However, 
to our knowledge, our study provides the largest set of OCT data from post marketing fingolimod-treated patients so 
far. 
Conclusions
Macular oedema did not develop in any of the studied patients. We found a small statistically significant increase in 
macular thickness, which did not affect the visual acuity or visual perception. Altogether, we do not consider the 
change clinically relevant and a causative role of fingolimod is not certain. Thus, our results do not underpin the need 
for routine screening for macular oedema in asymptomatic MS patients without diabetes or uveitis receiving 0.5 mg 
fingolimod daily. 
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Table 1
Demographics and clinical features
Age, years mean ± SD 42.3 ± 10.7
Female, n (%) 63 (66.3)
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Spheric -0.73 ± 2.01Refraction*, mean ± SD
Cylinder -0.81 ± 0.72
Former ON (%) 21 (22.1)
Cataract surgery (%) 1 (1.1)
Former MS treatment (%) Interferon β-1a (Avonex/Rebif) 62 (65.3)
Glatirameracetat (Copaxone) 22 (23.2)
Natalizumab (Tysabri) 17 (17.9)
Teriflunomid (Aubagio) 14 (14.7)
Other 9 (9.5)
Abbreviations: SD, standard deviation; ON, opticus neuritis; MS, multiple sclerosis. * Measured in dioptries
Table 2
Average retinal thickness comparison between baseline and follow-up
n 
(eyes)
Mean pre ± SD Mean post ± SD Mean difference (95% 
conf.interval)
p-Value
TMV (mm3) 178 7.38 ± 0.41 7.43 ± 0.42 0.05 (0.03, 0.07) < 0.001
Avth (μm) 178 261.0 ± 14.5 262.8 ± 14.8 1.87 (1.00, 2.74) < 0.001
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TMT (μm) 190 2402 ± 135 2422 ± 141 19.7 (11.6, 27.7) < 0.001
Outer ring (μm) 190 1010 ± 63.4 1015 ± 63.8 4.85. (0.19, 9.52) 0.042
Inner ring (μm) 190 1157 ± 71.4 1169 ± 73.3 12.3 (7.81, 16.9) < 0.001
Abbreviations: pre, values at baseline; post, values 3-4 months after initiation of fingolimod treatment. SD; standard deviation; TMV, total macular 























Figur 2   
Bar chart showing numbers of eyes increasing (>0) or decreasing (≤0) in total macular volume (TMV) 3-4 
months after fingolimod treatment. 114 eyes increased and 64 decreased/stayed unchanged. 
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